Anti-inhibitor coagulant complex
- Generic Name
- Anti-inhibitor coagulant complex
- Brand Names
- Feiba
- Drug Type
- Biotech
- Unique Ingredient Identifier
- CS849DUN3M
- Background
Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex. It is used to control bleeding in hemophilia A and B patients with inhibitors.
- Indication
For use in the control of bleeding episodes, perioperative management, and routine prophylaxis against bleeding episodes in hemophilia A and B patients with inhibitors. It is not indicated in the absence of factor VIII or IX inhibitors.
- Associated Conditions
- Bleeding caused by Hemophilia A, Bleeding caused by Hemophilia B, Perioperative bleeding caused by Hemophilia A, Perioperative bleeding caused by Hemophilia B
Hemophilia A and B Pipeline Advances with Novel Therapies in Clinical Trials
• Several companies are actively developing novel therapies for Hemophilia A and B, with many in various phases of clinical trials, showing promise for improving treatment options.
• TiumBio Co., Ltd. has submitted a Clinical Trial Application to initiate a Phase 1b investigation of TU7710, a new recombinant activated factor VII for hemophilia patients with inhibitors.
• The FDA approved ALTUVIIIO (efanesoctocog alfa) in February 2023, a factor VIII replacement therapy for adults and children with Hemophilia A, for routine prophylaxis and on-demand treatment.
• BioMarin received FDA approval for Roctavian in June 2023, a single-dose gene therapy for severe Hemophilia A, marking a significant advancement in treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath